Pharma marketing plays it safe while other industries innovate. Michael Stevenson, Managing Partner at Mr Wolf, explores how Challenger Brand theory can fix pharma’s stale, risk-averse advertising approach.

In a world where uncertainty gnaws at consumer confidence and ever-shrinking marketing budgets lead to anaemic growth, brands everywhere face a stark challenge: achieve more with less or risk becoming irrelevant. Thankfully that notion is already the cornerstone of a successful cohort of brands that provide a blueprint for growth – we know them as Challenger Brands.

Challenger Brands are the Davids to the market-leading Goliaths – they have a fraction of the budget and market share of the big brands, yet they defy gravity, outmanoeuvring with creativity, grit, and smarter thinking. And it’s not by happenstance – these brands follow a set of edicts that can be employed by anyone to bolster sales, drive customer acquisition and ultimately build your brand with greater efficiency.

Inexplicably, this approach appears largely absent in the pharmaceutical category. In fact, for a category that has innovation in its blood, pharma remains the exception to the rule. An industry that’s responsible for life-changing medications and treatments should be the beacon for brand and advertising excellence, but it’s often stuck using outdated paradigms. While other brands thrive on audacity and ingenuity, pharma advertising often remains shackled to uninspired, risk-averse formulas. Pharma advertising is sick. And it’s time for a radical cure.

There are several core tenets that successful Challenger Brands follow to unlock an unfair share – these include Cultivating an Enemy, Inciting a Movement, Poking the Bear, Following a True North and Leading the Thinking, to name a few. Like all tools these rules are only as good as the person who uses them, but if deployed correctly they can help smaller brands carve out a distinctive and enduring niche.

Even with a clear brand strategy in place, the proof is ultimately in the pudding. Pharma advertising needs to embrace creativity, to find a more authentic voice.  Brands need to focus on connecting with their audiences on a human level, beyond just the clinical. Understanding Challenger Brand theory can help provide the guardrails for this, mapping out a path to communication that is emotionally engaging, distinctive and ultimately more effective at propelling business forward. 

Healthcare consumers are no longer passive recipients, they are informed, empowered, and seeking relationships. They crave brands that share their values and stand for something bigger. They demand more, and Pharma needs to deliver compelling emotional stories with a deeper sense of purpose to reflect this.

Success for Pharma brands starts with having a clear understanding of what your brand stands for, what bigger role it will play in consumers’ lives, and how a distinctive position can translate into a more robust B2B and B2C approach. It comes to life for the consumer with purpose led, boldly transparent and emotionally salient communication.

Perhaps it’s time to rewrite the prescription for Pharma advertising. To trade tired cliches for creative conviction and emotional resonance. The industry can – and must – inject its brand communications with the same vigour it brings to medical breakthroughs. Only then will Pharma advertising recover its pulse and win genuine loyalty.

See more News and Articles at our News page

See more from Michael Stevenson at LinkedIn